Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Public ClinicalTrials.gov record NCT02226172. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Study identification
- NCT ID
- NCT02226172
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 21 participants
Conditions and interventions
Interventions
- Glasdegib (PF-04449913) Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 5, 2014
- Primary completion
- Dec 13, 2016
- Completion
- Jan 30, 2018
- Last update posted
- Jan 16, 2019
2014 – 2018
United States locations
- U.S. sites
- 15
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Building - Phoenix | Phoenix | Arizona | 85054 | — |
| Mayo Clinic Hospital | Phoenix | Arizona | 85054 | — |
| Mayo Clinic | Scottsdale | Arizona | 85259 | — |
| UC San Diego Moores Cancer Center - Investigational Drug Services | La Jolla | California | 92037-0845 | — |
| UCSD Medical Center Clinical Laboratory - La Jolla | La Jolla | California | 92037 | — |
| University of California San Diego (UCSD) Moores Cancer Center | La Jolla | California | 92093-0698 | — |
| UC San Diego Medical Center- Hillcrest | San Diego | California | 92103 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Weill Cornell Medical College - New York-Presbyterian Hospital | New York | New York | 10021 | — |
| Herbert Irving Comprehensive Cancer Center-Columbia University Medical Center | New York | New York | 10032 | — |
| Weill Cornell Medical College-New York Presbyterian Hospital | New York | New York | 10065 | — |
| Cleveland Clinic - Taussig Cancer Institute | Cleveland | Ohio | 44195 | — |
| Huntsman Cancer Institute-University of Utah | Salt Lake City | Utah | 84112 | — |
| University of Utah, Huntsman Cancer Hospital | Salt Lake City | Utah | 84112 | — |
| Froedtert Hospital and Medical College of Wisconsin | Milwaukee | Wisconsin | 53226-3522 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02226172, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 16, 2019 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02226172 live on ClinicalTrials.gov.